These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 8369784)

  • 1. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
    Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
    Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    Hong Kong Chest Service/British Medical Research Council
    Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2002 Feb; 233(1-2):169-77. PubMed ID: 11897421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
    Ul-Ain Q; Sharma S; Khuller GK
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3005-7. PubMed ID: 12937014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
    Schaberg T; Lode H
    Z Gesamte Inn Med; 1991 Jun; 46(8):276-9. PubMed ID: 1897286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
    Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
    Ellard GA; Ellard DR; Allen BW; Girling DJ; Nunn AJ; Teo SK; Tan TH; Ng HK; Chan SL
    Am Rev Respir Dis; 1986 Jun; 133(6):1076-80. PubMed ID: 3717760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
    Walubo A; Chan K; Woo J; Chan HS; Wong CL
    Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):551-6. PubMed ID: 1956210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazinamide serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
    Cowie RL; Brink BA
    S Afr Med J; 1990 Apr; 77(8):390-1. PubMed ID: 2184527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.